{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:40:00Z","timestamp":1792795200910,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00117-026-01659-7","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:11:44Z","timestamp":1791461504000},"page":"871-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kombination von Strahlentherapie und medikament\u00f6ser Tumortherapie in kurativer Intention","Combination of radiotherapy and medicinal anticancer therapy with curative intent"],"prefix":"10.1007","volume":"66","author":[{"given":"Mathias Alexander","family":"Sonnhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Klautke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"3","key":"1659_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7150\/ijms.3635","volume":"9","author":"R Baskar","year":"2012","unstructured":"Baskar\u00a0R et\u00a0al (2012) Cancer and radiation therapy: current advances and future directions. Int J Med Sci 9(3):193\u2013199","journal-title":"Int J Med Sci"},{"issue":"33-34","key":"1659_CR2","first-page":"570","volume":"119","author":"M Ghadimi","year":"2022","unstructured":"Ghadimi\u00a0M et\u00a0al (2022) Multimodal Treatment of Rectal Cancer. Dtsch Arztebl Int 119(33-34):570\u2013580","journal-title":"Dtsch Arztebl Int"},{"issue":"33","key":"1659_CR3","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.3748\/wjg.v25.i33.4850","volume":"25","author":"G Feeney","year":"2019","unstructured":"Feeney\u00a0G et\u00a0al (2019) Neoadjuvant radiotherapy for rectal cancer management. World J Gastroenterol 25(33):4850\u20134869","journal-title":"World J Gastroenterol"},{"issue":"17","key":"1659_CR4","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer\u00a0R et\u00a0al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N\u00a0Engl J Med 351(17):1731\u20131740","journal-title":"N Engl J Med"},{"key":"1659_CR5","doi-asserted-by":"crossref","unstructured":"Fietkau\u00a0R et\u00a0al Randomized phase\u00a0III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial. Journal of Clinical Oncology 40(16_suppl):4008\u20134008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008"},{"issue":"7","key":"1659_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ctrv.2010.03.002","volume":"36","author":"F Fiorica","year":"2010","unstructured":"Fiorica\u00a0F et\u00a0al (2010) Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev 36(7):539\u2013549","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"1659_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/bjs.8702","volume":"99","author":"ST Martin","year":"2012","unstructured":"Martin\u00a0ST, Heneghan\u00a0HM, Winter\u00a0DC (2012) Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 99(7):918\u2013928","journal-title":"Br J Surg"},{"issue":"34","key":"1659_CR8","doi-asserted-by":"publisher","first-page":"8688","DOI":"10.1200\/JCO.2005.02.1329","volume":"23","author":"C R\u00f6del","year":"2005","unstructured":"R\u00f6del\u00a0C et\u00a0al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J\u00a0Clin Oncol 23(34):8688\u20138696","journal-title":"J Clin Oncol"},{"key":"1659_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2482-13-43","volume":"13","author":"L Schiffmann","year":"2013","unstructured":"Schiffmann\u00a0L et\u00a0al (2013) Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications. BMC Surg 13:43","journal-title":"BMC Surg"},{"issue":"10","key":"1659_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/bjs.5506","volume":"93","author":"K Bujko","year":"2006","unstructured":"Bujko\u00a0K et\u00a0al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93(10):1215\u20131223","journal-title":"Br J Surg"},{"issue":"3","key":"1659_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.radonc.2007.10.042","volume":"85","author":"G Klautke","year":"2007","unstructured":"Klautke\u00a0G et\u00a0al (2007) Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. Radiother Oncol 85(3):379\u2013384","journal-title":"Radiother Oncol"},{"issue":"9","key":"1659_CR12","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1245\/s10434-012-2327-1","volume":"19","author":"AM Wolthuis","year":"2012","unstructured":"Wolthuis\u00a0AM et\u00a0al (2012) Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol 19(9):2833\u20132841","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1659_CR13","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra\u00a0EA et\u00a0al (2023) Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5\u2011Year Follow-up of the RAPIDO Trial. Ann Surg 278(4):e766\u2013e772","journal-title":"Ann Surg"},{"issue":"5","key":"1659_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.23.01208","volume":"42","author":"FS Verheij","year":"2024","unstructured":"Verheij\u00a0FS et\u00a0al (2024) Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. Journal of Clinical Oncology 42(5):500\u2013506","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"1659_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.5445","volume":"8","author":"E Fokas","year":"2022","unstructured":"Fokas\u00a0E et\u00a0al (2022) Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO\/ARO\/AIO-12 Randomized Clinical Trial. JAMA Oncol 8(1):e215445","journal-title":"JAMA Oncol"},{"issue":"9","key":"1659_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro\u00a0J et\u00a0al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090\u20131098","journal-title":"Lancet Oncol"},{"issue":"13","key":"1659_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly\u00a0RJ et\u00a0al (2021) Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N\u00a0Engl J Med 384(13):1191\u20131203","journal-title":"N Engl J Med"},{"key":"1659_CR18","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2147\/IDR.S177247","volume":"11","author":"M Haque","year":"2018","unstructured":"Haque\u00a0M et\u00a0al (2018) Health care-associated infections - an overview. Infect Drug Resist 11:2321\u20132333","journal-title":"Infect Drug Resist"},{"key":"1659_CR19","doi-asserted-by":"crossref","unstructured":"Chau I, C.B.-C., Chen M\u2011H et\u00a0al. , SKYSCRAPER-07: A\u00a0phase\u00a0III randomized study of atezolizumab with or without tiragolumab in patients with unresectable esophageal squamous cell carcinoma that has not progressed following definitive concurrent chemoradiotherapy. 2025: ESMO.","DOI":"10.1016\/j.annonc.2025.08.2716"},{"issue":"30","key":"1659_CR20","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO-24-01502","volume":"43","author":"R Fietkau","year":"2025","unstructured":"Fietkau\u00a0R et\u00a0al (2025) Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial. J\u00a0Clin Oncol 43(30):3266\u20133278","journal-title":"J Clin Oncol"},{"issue":"10","key":"1659_CR21","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","volume":"26","author":"QP Janssen","year":"2025","unstructured":"Janssen\u00a0QP et\u00a0al (2025) Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. The Lancet Oncology 26(10):1346\u20131356","journal-title":"The Lancet Oncology"},{"issue":"3","key":"1659_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41416-021-01624-2","volume":"126","author":"D Pietrasz","year":"2022","unstructured":"Pietrasz\u00a0D et\u00a0al (2022) Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Br J Cancer 126(3):440\u2013448","journal-title":"Br J Cancer"},{"issue":"1","key":"1659_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/hed.23542","volume":"37","author":"P Strojan","year":"2015","unstructured":"Strojan\u00a0P et\u00a0al (2015) Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. Head Neck 37(1):134\u2013150","journal-title":"Head Neck"},{"issue":"9","key":"1659_CR24","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.oraloncology.2014.06.014","volume":"50","author":"M Behera","year":"2014","unstructured":"Behera\u00a0M et\u00a0al (2014) Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. Oral Oncol 50(9):888\u2013894","journal-title":"Oral Oncol"},{"issue":"2","key":"1659_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.21873\/invivo.12769","volume":"36","author":"S Nassif","year":"2022","unstructured":"Nassif\u00a0S et\u00a0al (2022) Cisplatin Versus Carboplatin and Paclitaxel in Radiochemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma. In Vivo 36(2):821\u2013832","journal-title":"In Vivo"},{"key":"1659_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.radonc.2020.01.016","volume":"144","author":"R Fietkau","year":"2020","unstructured":"Fietkau\u00a0R et\u00a0al (2020) Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel\/cisplatin to standard radiotherapy with fluorouracil\/cisplatin: The PacCis-trial. Radiotherapy and Oncology 144:209\u2013217","journal-title":"Radiotherapy and Oncology"},{"issue":"2","key":"1659_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.radonc.2015.10.014","volume":"118","author":"W Budach","year":"2016","unstructured":"Budach\u00a0W et\u00a0al (2016) Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A\u00a0meta-analysis of randomized trials. Radiother Oncol 118(2):238\u2013243","journal-title":"Radiother Oncol"},{"key":"1659_CR28","doi-asserted-by":"crossref","unstructured":"Hecht, M., et\u00a0al., Safety and efficacy of single cycle induction treatment with cisplatin\/docetaxel\/ durvalumab\/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. J\u00a0Immunother Cancer, 2020. 8(2).","DOI":"10.1136\/jitc-2020-001378"},{"issue":"16","key":"1659_CR29","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1158\/1078-0432.CCR-20-0230","volume":"26","author":"J Weiss","year":"2020","unstructured":"Weiss\u00a0J et\u00a0al (2020) Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin Contraindication. Clin Cancer Res 26(16):4260\u20134267","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1659_CR30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/hed.20279","volume":"27","author":"J Bernier","year":"2005","unstructured":"Bernier\u00a0J et\u00a0al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10):843\u2013850","journal-title":"Head Neck"},{"issue":"19","key":"1659_CR31","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","volume":"350","author":"JS Cooper","year":"2004","unstructured":"Cooper\u00a0JS et\u00a0al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N\u00a0Engl J Med 350(19):1937\u20131944","journal-title":"N Engl J Med"},{"issue":"1","key":"1659_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri\u00a0R et\u00a0al (2025) Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N\u00a0Engl J Med 393(1):37\u201350","journal-title":"N Engl J Med"},{"issue":"4","key":"1659_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3857\/roj.2021.00507","volume":"39","author":"D Kim","year":"2021","unstructured":"Kim\u00a0D et\u00a0al (2021) Prognostic value of the maximum standardized uptake value for the locoregional control in early glottic cancer. Radiat Oncol\u00a0J 39(4):297\u2013303","journal-title":"Radiat Oncol J"},{"issue":"5","key":"1659_CR34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.ijrobp.2008.06.1935","volume":"73","author":"L Wang","year":"2009","unstructured":"Wang\u00a0L et\u00a0al (2009) The Effect of Radiation Dose and Chemotherapy on Overall Survival in 237 Patients With Stage III Non\u2013Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 73(5):1383\u20131390","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"1659_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00066-016-0941-8","volume":"192","author":"M Flentje","year":"2016","unstructured":"Flentje\u00a0M et\u00a0al (2016) GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol 192(4):216\u2013222","journal-title":"Strahlenther Onkol"},{"issue":"24","key":"1659_CR36","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia\u00a0SJ et\u00a0al (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine 379(24):2342\u20132350","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"1659_CR37","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia\u00a0SJ et\u00a0al (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N\u00a0Engl J Med 379(24):2342\u20132350","journal-title":"N Engl J Med"},{"issue":"12","key":"1659_CR38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel\u00a0DR et\u00a0al (2022) Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J\u00a0Clin Oncol 40(12):1301\u20131311","journal-title":"J Clin Oncol"},{"key":"1659_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110294","volume":"196","author":"F Zehentmayr","year":"2024","unstructured":"Zehentmayr\u00a0F et\u00a0al (2024) Durvalumab impacts progression-free survival while high-dose radiation \u3009\u202f66\u202fGy improves local control without excess toxicity in unresectable NSCLC stage\u00a0III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR). Radiother Oncol 196:110294","journal-title":"Radiother Oncol"},{"issue":"7","key":"1659_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu\u00a0S et\u00a0al (2024) Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N\u00a0Engl J Med 391(7):585\u2013597","journal-title":"N Engl J Med"},{"issue":"7","key":"1659_CR41","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1200\/JCO.2005.02.9793","volume":"24","author":"D De Ruysscher","year":"2006","unstructured":"De Ruysscher\u00a0D et\u00a0al (2006) Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J\u00a0Clin Oncol 24(7):1057\u20131063","journal-title":"J Clin Oncol"},{"issue":"14","key":"1659_CR42","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","volume":"20","author":"M Takada","year":"2002","unstructured":"Takada\u00a0M et\u00a0al (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J\u00a0Clin Oncol 20(14):3054\u20133060","journal-title":"J Clin Oncol"},{"issue":"14","key":"1659_CR43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng\u00a0Y et\u00a0al (2024) Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N\u00a0Engl J Med 391(14):1313\u20131327","journal-title":"N Engl J Med"},{"issue":"8","key":"1659_CR44","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","volume":"18","author":"WA Peters 3rd","year":"2000","unstructured":"Peters\u00a0WA 3rd et\u00a0al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J\u00a0Clin Oncol 18(8):1606\u20131613","journal-title":"J Clin Oncol"},{"issue":"15","key":"1659_CR45","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","volume":"340","author":"M Morris","year":"1999","unstructured":"Morris\u00a0M et\u00a0al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N\u00a0Engl J Med 340(15):1137\u20131143","journal-title":"N Engl J Med"},{"issue":"35","key":"1659_CR46","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration","year":"2008","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J\u00a0Clin Oncol 26(35):5802\u20135812","journal-title":"J Clin Oncol"},{"issue":"1","key":"1659_CR47","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ygyno.2014.04.049","volume":"134","author":"F Petrelli","year":"2014","unstructured":"Petrelli\u00a0F et\u00a0al (2014) Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. Gynecol Oncol 134(1):166\u2013171","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1659_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ygyno.2014.08.027","volume":"135","author":"EC Rijkmans","year":"2014","unstructured":"Rijkmans\u00a0EC et\u00a0al (2014) Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. Gynecol Oncol 135(2):231\u2013238","journal-title":"Gynecol Oncol"},{"issue":"10462","key":"1659_CR49","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","volume":"404","author":"M McCormack","year":"2024","unstructured":"McCormack\u00a0M et\u00a0al (2024) Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. Lancet 404(10462):1525\u20131535","journal-title":"Lancet"},{"key":"1659_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115375","volume":"220","author":"G Eminowicz","year":"2025","unstructured":"Eminowicz\u00a0G et\u00a0al (2025) Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial. Eur J Cancer 220:115375","journal-title":"Eur J Cancer"},{"issue":"10460","key":"1659_CR51","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"D Lorusso","year":"2024","unstructured":"Lorusso\u00a0D et\u00a0al (2024) Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 404(10460):1321\u20131332","journal-title":"The Lancet"},{"issue":"29","key":"1659_CR52","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","volume":"38","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo\u00a0A et\u00a0al (2020) Molecular Classification of the PORTEC\u20113 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J\u00a0Clin Oncol 38(29):3388\u20133397","journal-title":"J Clin Oncol"},{"issue":"5","key":"1659_CR53","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink\u00a0H et\u00a0al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a\u00a0phase\u00a0III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J\u00a0Clin Oncol 15(5):2040\u20132049","journal-title":"J Clin Oncol"},{"issue":"9","key":"1659_CR54","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam\u00a0M et\u00a0al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J\u00a0Clin Oncol 14(9):2527\u20132539","journal-title":"J Clin Oncol"},{"issue":"35","key":"1659_CR55","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson\u00a0LL et\u00a0al (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin. J\u00a0Clin Oncol 30(35):4344\u20134351","journal-title":"J Clin Oncol"},{"issue":"6","key":"1659_CR56","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James\u00a0RD et\u00a0al (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial. Lancet Oncol 14(6):516\u2013524","journal-title":"Lancet Oncol"},{"issue":"7","key":"1659_CR57","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00066-018-1396-x","volume":"195","author":"OJ Ott","year":"2019","unstructured":"Ott\u00a0OJ et\u00a0al (2019) Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. Strahlenther Onkol 195(7):607\u2013614","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"1659_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","volume":"118","author":"K Br\u00fcck","year":"2024","unstructured":"Br\u00fcck\u00a0K et\u00a0al (2024) Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study. Int J Radiat Oncol Biol Phys 118(1):41\u201349","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1659_CR59","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijrobp.2024.08.036","volume":"121","author":"PP Avolio","year":"2025","unstructured":"Avolio\u00a0PP et\u00a0al (2025) Effect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys 121(2):317\u2013324","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1659_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104557","volume":"205","author":"C Baudelin","year":"2025","unstructured":"Baudelin\u00a0C et\u00a0al (2025) Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials. Crit Rev Oncol Hematol 205:104557","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"1659_CR61","doi-asserted-by":"publisher","first-page":"e1341","DOI":"10.1634\/theoncologist.2018-0280","volume":"24","author":"R Merten","year":"2019","unstructured":"Merten\u00a0R et\u00a0al (2019) Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist 24(12):e1341\u2013e1350","journal-title":"Oncologist"},{"key":"1659_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102586","volume":"119","author":"C Becherini","year":"2023","unstructured":"Becherini\u00a0C et\u00a0al (2023) Safety profile of cyclin-dependent kinase (CDK) 4\/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis. Cancer Treat Rev 119:102586","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1659_CR63","first-page":"121","volume":"147","author":"J Fodor","year":"2006","unstructured":"Fodor\u00a0J (2006) Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment. Orv Hetil 147(3):121\u2013125","journal-title":"Orv Hetil"},{"issue":"11","key":"1659_CR64","first-page":"4791","volume":"29","author":"M Ishitobi","year":"2009","unstructured":"Ishitobi\u00a0M et\u00a0al (2009) Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer. Anticancer Res 29(11):4791\u20134794","journal-title":"Anticancer Res"},{"issue":"11","key":"1659_CR65","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/cncr.28594","volume":"120","author":"M Roach 3rd","year":"2014","unstructured":"Roach\u00a0M 3rd (2014) Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer 120(11):1620\u20131629","journal-title":"Cancer"},{"issue":"2","key":"1659_CR66","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1012348","volume":"365","author":"CU Jones","year":"2011","unstructured":"Jones\u00a0CU et\u00a0al (2011) Radiotherapy and short-term androgen deprivation for localized prostate cancer. N\u00a0Engl J Med 365(2):107\u2013118","journal-title":"N Engl J Med"},{"key":"1659_CR67","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K. and AWMF) (2021) S3-Leitlinie Prostatakarzinom, Langversion 6.2, AWMF Registernummer: 043\/022OL."},{"key":"1659_CR68","doi-asserted-by":"crossref","unstructured":"Bolla, M., et\u00a0al., Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med, 2009. 360(24): p.\u00a02516\u201327.","DOI":"10.1056\/NEJMoa0810095"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-026-01659-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-026-01659-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-026-01659-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:02:07Z","timestamp":1792792927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-026-01659-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1659"],"URL":"https:\/\/doi.org\/10.1007\/s00117-026-01659-7","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"8 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Sonnhoff:\n                      A. Finanzielle Interessen: IMAGINE-Niedersachsen (E-Mail IMAGINE@mh-hannover.de) MHH 01KD2401A . \u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmender: Aurikamed, Fortbildungsagentur. \u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u00e4.: Novocure, Servier, ohne inhaltlichen Bezug zum Artikel. \u2013 B. Nichtfinanzielle Interessen: Niedergelassener Strahlentherapeut, wissenschaftlicher Mitarbeiter der MHH | Mitgliedschaften: DEGRO, DeGBS, BVDST, F\u00f6rderer \u00dcberseemuseum Bremen.\n                      H.\u00a0Christiansen:\n                      A. Finanzielle Interessen: AstraZeneca, Fortbildung in der GHE, MSD, NewConceptOncology, Onkologischer Arbeitskreis Hannover | (Honorare f\u00fcr Vortr\u00e4ge\/Moderationen\/Aktive Teilnahme an AdBoards). \u2013 B. Nichtfinanzielle Interessen: Medizinische Hochschule Hannover \u2013 Angestellt als Direktor der Klinik f\u00fcr Strahlentherapie und Spezielle Onkologie | MVZ der MHH GmbH \u2013 Angestellter Facharzt | Mitgliedschaften: \u00c4rztekammer Niedersachsen, \u00c4rztliche Stelle Niedersachsen \/ Bremen, Deutsche Gesellschaft f\u00fcr Radioonkologie (DEGRO) \u2013 Sprecher der DEGRO-Akademie f\u00fcr Fort- und Weiterbildung in der Radioonkologie, Bundesverband der deutschen Strahlentherapeuten (BVDST), European Society for Radiotherapy & Oncology (ESTRO), Gesellschaft f\u00fcr Biologische Strahlenforschung (GBS), Gesellschaft f\u00fcr P\u00e4diatrische H\u00e4matologie und Onkologie (GPOH), Deutsche Krebsgesellschaft (DKG), Nieders\u00e4chsische Krebsgesellschaft (NKG), Onkologischer Arbeitskreis Hannover (OAK), Deutscher Hochschulverband (DHV), Marburger Bund Niedersachsen.\n                      G.\u00a0Glautke:\n                      A. Finanzielle Interessen: Vortragshonorare von Merck, BMS, BrainLap, Sennewaldt Medizintechnik, AstraZeneca. \u2013 B. Nichtfinanzielle Interessen: Chefarzt der Klinik und Praxis f\u00fcr Radioonkologie, Chemnitz | Mitglied des gesch\u00e4ftsf\u00fchrenden Direktoriums des Onkologischen Zentrum Chemnitz | Mitgliedschaften: DEGRO, BVDST, Dt. R\u00f6ntgengesellschaft | Vorstandsmitglied der DEGRO - Akademie; Vertreter der DEGRO bzw. des BVDST in der Zertifizierungskommission gastrointestinale Tumoren; Vertreter der DEGRO bzw. des BVDST in der aktuellen Leitlinie Colorektales Karzinom sowie Analkarzinom.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}